JSPR, JSPRW · CIK 0001788028 · operating
Jasper Therapeutics is a clinical-stage biotechnology company developing monoclonal antibody therapeutics targeting mast cell and hematopoietic stem cell-driven diseases. The company's lead candidate, briquilimab, is designed to block stem cell factor signaling through the CD117 receptor on mast and stem cells. This mechanism targets multiple therapeutic areas including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning regimens for stem cell transplantation in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency.
The company is incorporated in Delaware and headquartered in Redwood City, California. As of the latest available data, Jasper operates with a team of 27 full-time employees. The company is listed on Nasdaq and remains in clinical development stage, with no disclosed commercial revenue.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-4.89 | $-4.89 | +20.9% | |
| 2023 | $-6.18 | $-6.18 | -500.0% | |
| 2022 | $-1.03 | $-1.03 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-02-28 | 0001213900-25-018384 | SEC ↗ |
| 2023-12-31 | 2024-03-05 | 0001213900-24-020114 | SEC ↗ |
| 2022-12-31 | 2023-03-08 | 0001213900-23-018542 | SEC ↗ |
| 2021-12-31 | 2022-03-18 | 0001213900-22-013592 | SEC ↗ |
| 2020-12-31 | 2021-03-30 | 0001213900-21-018735 | SEC ↗ |
| 2019-12-31 | 2020-03-26 | 0001213900-20-007505 | SEC ↗ |